Categories
Change Password!
Reset Password!
This study was aimed to find the efficacy of erenumab at the ≥50%, ≥75%, and 100% decrease in MMD response thresholds.
From a recent study, it was evaluated that
erenumab is effective to treat patients with episodic migraine. It was depicted
that Erenumab treatment groups attained better monthly migraine days (MMD)
responses than placebo.
This study was aimed to find the efficacy of
erenumab at the ≥50%, ≥75%, and 100% decrease in MMD response thresholds.
In this study, the efficiency of erenumab at ≥50%, ≥75%, and
100% fall in MMD response thresholds was evaluated. Patients with episodic
migraine were randomized into the ratio of 1:1:1 to erenumab 70 mg, erenumab
140 mg or placebo once monthly.
Patients who executed responses at the ≥50%, ≥75%, or 100% thresholds showed greater drops in migraine days and in migraine-specific medicines use as well as considerable progress in headache impact and migraine-related disability and as determined by the decrease in mMIDAS, HIT-6 and MPFID test scores as compared with the general erenumab-treated people.
Table-
Showing response threshold
The administration of erenumab worked
effectively for patients with episodic migraine.
Headache
The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response
Gregor Broessner et al.
Comments (0)